Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy

European Respiratory Journal

Volumn 33, Issue 6, 2009, Pages 1518-1519

  Hoeper, M M ^a   Olsson, K M ^a   Schneider, A ^a   Golpon, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BOSENTAN; DIGOXIGENIN; PREDNISOLONE; SITAXSENTAN;

ABDOMINAL DISCOMFORT; ADULT; BILIRUBIN BLOOD LEVEL; BODY HEIGHT; BODY WEIGHT; CASE REPORT; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ECHOGRAPHY; EISENMENGER COMPLEX; EXERCISE; FEMALE; FOLLOW UP; HEART VENTRICLE SEPTUM DEFECT; HEPATITIS; HUMAN; LETTER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEROLOGY; SIDE EFFECT; TREATMENT DURATION;

EISENMENGER COMPLEX; FEMALE; GLUCOCORTICOIDS; HEPATITIS, TOXIC; HUMANS; ISOXAZOLES; LIVER FUNCTION TESTS; RECEPTORS, ENDOTHELIN; THIOPHENES; YOUNG ADULT;

EID: 69249146238     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00193308     Document Type: Letter

References (6)

1. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-414.
2. Wilkins MR, Wharton J, Grimminger F, et al. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008; 32: 198-209.
3. Olschewski H, Gomberg-Maitland M. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 801-901.
4. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-344.
5. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69: 223-231.
6. Benza RL, Mehta S, Keogh A, et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007; 26: 63-69.